WuXi picks Massachusetts for first U.S. manufacturing site

WuXi Biologics Inc. (HKSE:2269) said it will invest $60 million to construct a biologics production facility in Worcester, Mass. The manufacturing site will be WuXi Biologics' first in the U.S., and 11th overall.

The company plans to hire 150 employees at the site, where it will conduct clinical and small volume commercial production using single-use bioreactors. WuXi said the facility will be the first U.S. site with continuous bioprocessing capabilities, and will have an early stage bioprocess development lab...